Drugs / SBI-087
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00714116 | Mar 2009 → Sep 2012 | systemic lupus erythematosus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00815906 | Dec 2008 → Apr 2012 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00641225 | Mar 2008 → Mar 2011 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01008852 | Dec 2009 → Sep 2011 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SBI-087 | “Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis” NCT01008852 ↗ |
| Action | Deplete | “has been reported to deplete B cells” PMID 27112532 ↗ Apr 2016 |
| Modality | Protein / enzyme biologic | “SBI-087 is a Small Modular Immunopharmaceutical Protein™(SMIP™) drug” PMID 27112532 ↗ Apr 2016 |
| Route | Intravenous | “administered intravenously or subcutaneously” PMID 27112532 ↗ Apr 2016 |
| Route | Subcutaneous | “administered intravenously or subcutaneously” PMID 27112532 ↗ Apr 2016 |